8-K: Aquestive Therapeutics Announces Positive Topline Data for Anaphylm Sublingual Film

Aquestive Therapeutics reports positive pharmacokinetic data from a self-administration study of Anaphylm, its sublingual epinephrine film for severe allergic reactions.

Summary

• Aquestive Therapeutics has released positive topline pharmacokinetic (PK) data from a self-administration study of Anaphylm, an epinephrine sublingual film.
• The study compared self-administered Anaphylm, healthcare provider (HCP) administered Anaphylm, and HCP administered intramuscular (IM) Adrenalin injections in 36 healthy adults.
• The results showed no statistical difference in epinephrine absorption between self-administered and HCP-administered Anaphylm.
• The median time to maximum concentration (Tmax) was 15 minutes for both Anaphylm administration methods, compared to 50 minutes for the IM injection.
• The company is maintaining its guidance for a full product launch of Anaphylm at the end of 2025 or in the first quarter of 2026.
• This timeline is based on filing a New Drug Application (NDA) late in the fourth quarter of 2024 or early in the first quarter of 2025.
• Anaphylm is being developed as a non-invasive, orally delivered epinephrine treatment for severe allergic reactions, including anaphylaxis.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results and a clear path forward for product development, indicating a strong positive sentiment. However, there are still risks associated with regulatory approval and commercialization.

Positives

• The self-administration study results show that Anaphylm is easy to use and can be administered effectively by patients themselves.
• Anaphylm's rapid absorption, with a Tmax of 15 minutes, is a significant advantage over traditional intramuscular injections.
• The product is designed to be easy to carry and use, addressing potential real-world emergency scenarios.
• The company is on track with its timeline for NDA submission and product launch.
• Anaphylm is a novel approach to epinephrine delivery, potentially improving treatment for anaphylaxis.

Negatives

• The company still needs to complete the Oral Allergy Syndrome (OAS) challenge study, which is expected to be completed late in the third quarter or early fourth quarter of 2024.
• The product is still subject to FDA approval, and there is a risk that the FDA may require additional clinical studies.
• The company faces risks associated with commercializing a new product, including market acceptance and competition.

Risks

• There are risks associated with delays or changes to the timing, cost, and success of product development activities and clinical trials for Anaphylm.
• The company may not be able to generate sufficient data for FDA approval of Anaphylm.
• The FDA may require additional clinical studies for approval of Anaphylm.
• There is a risk of delays in or failure to receive FDA approval of Anaphylm.
• The company faces competition from other products in the market.
• There are risks associated with commercializing a new product, including technology, financial, market, and implementation risks.
• The company needs sufficient capital and cash resources to fund clinical development activities.
• The company faces the risk of eroding market share for Suboxone, which is a significant source of current revenue.
• There are risks associated with intellectual property rights and infringement claims.
• General economic, political, business, industry, regulatory, financial, and market conditions could impact the company.

Future Outlook

Aquestive is focused on completing the remaining clinical studies and submitting an NDA for Anaphylm, with a goal of launching the product by the end of 2025 or early 2026. The company is also working on other products in its pipeline.

Management Comments

• Daniel Barber, President & Chief Executive Officer of Aquestive, stated that the self-administration data demonstrates the versatility of Anaphylm as a product that is easy to remember, carry, and use.
• Daniel Barber also noted that the Anaphylm formulation indicates that rapid and substantial epinephrine absorption is achieved under a variety of administration conditions.
• Matthew Greenhawt, MD, MBA, MSc, an anaphylaxis expert, and allergist at Childrens Hospital Colorado and Aquestive Scientific Advisory Board member, said that an orally administered product that can be rapidly and easily administered has the potential to be a game-changer for the allergy community.

Industry Context

This announcement is significant as it highlights a potential new method for delivering epinephrine, a critical medication for anaphylaxis. The current standard of care is epinephrine injection, which can be inconvenient and difficult for some patients. Anaphylm, if approved, could offer a more user-friendly alternative.

Comparison to Industry Standards

• The current standard treatment for anaphylaxis is epinephrine injection, typically administered via auto-injectors like EpiPen or Auvi-Q.
• These auto-injectors have limitations, including the need for injection, which can be a barrier for some patients, and the risk of needle-related injuries.
• Anaphylm's sublingual film delivery method offers a non-invasive alternative, potentially improving patient compliance and ease of use.
• The rapid absorption of epinephrine with Anaphylm, achieving a Tmax of 15 minutes, is comparable to or faster than some auto-injector products.
• Companies like Mylan (now Viatris) and Kaleo have dominated the epinephrine auto-injector market, and Anaphylm could disrupt this market with its novel delivery method.

Stakeholder Impact

• Shareholders will be positively impacted by the positive clinical trial results and the potential for a new product launch.
• Patients with severe allergies will benefit from a new, non-invasive treatment option.
• Healthcare providers will have a new tool for managing anaphylaxis.
• Employees of Aquestive will be involved in the development and commercialization of Anaphylm.

Next Steps

• Complete the Oral Allergy Syndrome (OAS) challenge study.
• Request a pre-NDA meeting with the FDA.
• File the New Drug Application (NDA) for Anaphylm.
• Prepare for the full product launch of Anaphylm.

Key Dates

Keywords

Anaphylm, epinephrine, sublingual film, anaphylaxis, pharmacokinetics, FDA, clinical trial, allergy, oral delivery, NDA